Clinical Trial Update: Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating dapagliflozin for improving cardiac function after anterior myocardial infarction in non-diabetic patients; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: Omar Younis | Conditions: Anterior MI | Phase 2, Phase 3 | Status: COMPLETED